Fig. 2

Arterial occlusive event (AOE) rates with ponatinib. A Rates of non-adjudicated and adjudicated AOEs. B Exposure-adjusted incidence of newly occurring arterial occlusive events (AOEs) by year (all patients). Later intervals excluded patients with prior events. Non-adjudicated values were published previously [3]. C Incidence of AOEs (adjudicated) by number of baseline risk factors (all patients). Risk factors included arterial hypertension, hypercholesterolemia, obesity, diabetes mellitus, non-ischemic cardiac disease, and ischemic disease. D Overall survival (OS) in chronic-phase chronic myeloid leukemia (CP-CML) patients with and without AOEs